Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | F2 | P00734 | 14/20 | 0.52 |
| ▸ | F11 | P03951 | 2/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | F9 | P00740 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MASP2 | O00187 | 1/20 | 0.45 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203359 | 0.88 | CYP3A4 (0.59) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL4199551 | 0.86 | F2 (0.51) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL4199158 | 0.85 | CYP3A4 (0.52) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL4209391 | 0.85 | CYP3A4 (0.63) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL4196730 | 0.84 | CYP3A4 (0.51) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL6079393 | 0.79 | CYP3A4 (0.72) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL641343 | 0.77 | CYP3A4 (0.71) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL642219 | 0.77 | CYP3A4 (0.71) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL8147881 | 0.77 | CYP3A4 (0.71) | CYP3A4F2F11KLKB1PRSS1 | |
| SCHEMBL643246 | 0.76 | CYP3A4 (1.00) | CYP3A4F2F11KLKB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | TFPI, TFPI2, ADAMTS1 | CYP3A4 228/4885F2 23/4885F11 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.